vorinostat has been researched along with Pruritus in 3 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Pruritus: An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) were evaluated in patients with refractory cutaneous T-cell lymphoma (CTCL)." | 9.12 | Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). ( Chiao, JH; Duvic, M; Frankel, SR; Hazarika, P; Kelly, C; Ni, X; Reilly, JF; Richon, VM; Ricker, JL; Talpur, R; Zhang, C, 2007) |
| "To discuss vorinostat approval for treatment of cutaneous manifestations of advanced cutaneous T-cell lymphoma (CTCL)." | 7.74 | Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. ( Abraham, S; Booth, BP; Dagher, R; Farrell, A; Harapanhalli, RS; He, K; Jee, JM; Johnson, JR; Justice, R; Mann, BS; Morse, DE; Pazdur, R; Pope, S; Sridhara, R; Verbois, L, 2007) |
| "The activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) were evaluated in patients with refractory cutaneous T-cell lymphoma (CTCL)." | 5.12 | Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). ( Chiao, JH; Duvic, M; Frankel, SR; Hazarika, P; Kelly, C; Ni, X; Reilly, JF; Richon, VM; Ricker, JL; Talpur, R; Zhang, C, 2007) |
| "To discuss vorinostat approval for treatment of cutaneous manifestations of advanced cutaneous T-cell lymphoma (CTCL)." | 3.74 | Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. ( Abraham, S; Booth, BP; Dagher, R; Farrell, A; Harapanhalli, RS; He, K; Jee, JM; Johnson, JR; Justice, R; Mann, BS; Morse, DE; Pazdur, R; Pope, S; Sridhara, R; Verbois, L, 2007) |
| "Pruritus is one of the cardinal symptoms found in patients with leukemic cutaneous T cell lymphoma (CTCL)." | 1.42 | Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities. ( Benoit, BM; Cedeno-Laurent, F; Kim, EJ; Rook, AH; Singer, EM; Vittorio, CC; Wysocka, M; Yosipovitch, G, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cedeno-Laurent, F | 1 |
| Singer, EM | 1 |
| Wysocka, M | 1 |
| Benoit, BM | 1 |
| Vittorio, CC | 1 |
| Kim, EJ | 1 |
| Yosipovitch, G | 1 |
| Rook, AH | 1 |
| Duvic, M | 1 |
| Talpur, R | 1 |
| Ni, X | 1 |
| Zhang, C | 1 |
| Hazarika, P | 1 |
| Kelly, C | 1 |
| Chiao, JH | 1 |
| Reilly, JF | 1 |
| Ricker, JL | 1 |
| Richon, VM | 1 |
| Frankel, SR | 1 |
| Mann, BS | 1 |
| Johnson, JR | 1 |
| He, K | 1 |
| Sridhara, R | 1 |
| Abraham, S | 1 |
| Booth, BP | 1 |
| Verbois, L | 1 |
| Morse, DE | 1 |
| Jee, JM | 1 |
| Pope, S | 1 |
| Harapanhalli, RS | 1 |
| Dagher, R | 1 |
| Farrell, A | 1 |
| Justice, R | 1 |
| Pazdur, R | 1 |
1 trial available for vorinostat and Pruritus
| Article | Year |
|---|---|
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dehydration; Disease Progression; Disease-Fre | 2007 |
2 other studies available for vorinostat and Pruritus
| Article | Year |
|---|---|
Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities.
Topics: Adult; Aged; Aged, 80 and over; Depsipeptides; Dexamethasone; Female; Histone Deacetylase Inhibitors | 2015 |
Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma.
Topics: Animals; Anticarcinogenic Agents; Cats; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II | 2007 |